GC B cells are not detectable after RTX treatment. (A) Contour plots of CD19 and CD20 on lymphocytes from iliac lymph node of RTX-treated patients and controls. The number (B) and proportion (C) of CD20⁺ B cells in the lymph nodes of RTX-treated patients and controls. Contour plots (D), the percentage (E), and total number (F) of CD38⁺Bcl-6⁺CD19⁺ GC B cells in the lymph nodes of RTX-treated patients and controls. (G) Mean fluorescence intensity of CD20 on CD38⁻Bcl-6⁻ non-GC B cells and CD38⁺Bcl-6⁺ GC B cells from control patients. (H) Mean fluorescence intensity of CD20 on CD19⁺ lymph node B cells from RTX-treated patients and controls. In bar graphs, one symbol represents one individual, and the height of the bar represents the mean.